These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17362385)

  • 1. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
    Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
    Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor antibodies in ovarian cancer.
    Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
    Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
    Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
    Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-ovarian antibodies in sera of patients with ovarian tumors.
    Szubert S; Michalak S; Szpurek D; Moszynski R; Krygowska-Zielinska J; Sajdak S
    Immunol Lett; 2012 Dec; 148(2):133-7. PubMed ID: 23026238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.
    Chinni SR; Falchetto R; Gercel-Taylor C; Shabanowitz J; Hunt DF; Taylor DD
    Clin Cancer Res; 1997 Sep; 3(9):1557-64. PubMed ID: 9815843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
    Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
    Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
    Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
    Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
    Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
    Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
    Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
    Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Autoantibodies to steroid-producing ovarian cells in cancer patients].
    Bershteĭn LM; Poroshina TE; Vasil'ev DA; Orlova AV
    Vopr Onkol; 2008; 54(5):602-5. PubMed ID: 19069474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
    Taylor DD; Lyons KS; Gerçel-Taylor C
    Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serological analysis of antibodies by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma].
    Feng J; Lü J; Qian H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Aug; 31(8):493-5. PubMed ID: 9275445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
    Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
    Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of immune responses to ovarian tumor antigens by multiparity.
    Shields LB; Gerçel-Taylor C; Yashar CM; Wan TC; Katsanis WA; Spinnato JA; Taylor DD
    J Soc Gynecol Investig; 1997; 4(6):298-304. PubMed ID: 9408885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical importance of serum anti-p53 antibodies as tumor markers].
    Sakai H; Okamoto E
    Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
    Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
    Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer.
    Gerçel-Taylor C; Bazzett LB; Taylor DD
    Gynecol Oncol; 2001 Apr; 81(1):71-6. PubMed ID: 11277653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers.
    Korneeva I; Bongiovanni AM; Girotra M; Caputo TA; Witkin SS
    Am J Obstet Gynecol; 2000 Jul; 183(1):18-21. PubMed ID: 10920302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.